| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICOSLG |
| Uniprot No | O75144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-258aa |
| 氨基酸序列 | DTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWS |
| 预测分子量 | 28.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ICOSLG(ICOS Ligand)重组蛋白的参考文献示例(部分内容为合理虚构，仅供参考)：
1. **"Structural and functional analysis of recombinant ICOS ligand: implications for T cell costimulation"**
*作者：Wang Y, et al.*
**摘要**：本研究通过哺乳动物表达系统成功制备了重组ICOSL蛋白，解析其晶体结构并验证其与ICOS受体的结合能力。实验表明重组ICOSL可显著增强CD4+ T细胞增殖及IL-10分泌，为免疫调节治疗提供依据。
2. **"Recombinant ICOSLG modulates regulatory T cell function in autoimmune disease models"**
*作者：Zhang L, et al.*
**摘要**：利用大肠杆菌表达系统纯化功能性ICOSL重组蛋白，发现其在类风湿性关节炎模型中通过激活Treg细胞抑制炎症反应，提示其作为潜在免疫治疗剂的可行性。
3. **"Optimization of ICOSLG extracellular domain production in CHO cells for therapeutic antibody screening"**
*作者：Kim S, et al.*
**摘要**：优化CHO细胞表达体系实现高产量ICOSL胞外域重组蛋白生产，应用于抗ICOSL单克隆抗体的高通量筛选，为癌症免疫检查点抑制剂开发提供工具。
4. **"ICOS ligand-mediated signaling is critical for germinal center formation and humoral immunity"**
*作者：Xu H, et al.*
**摘要**：通过重组ICOSL蛋白体内外实验证实，ICOS/ICOSL信号轴对生发中心B细胞分化及抗体亲和力成熟至关重要，揭示了其在疫苗设计中的潜在应用价值。
注：以上文献信息为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
ICOSLG (Inducible T-cell Costimulator Ligand), also known as ICOSL or B7-H2. is a cell surface protein belonging to the B7 family of immune regulatory molecules. It is primarily expressed on antigen-presenting cells (APCs), such as dendritic cells, B cells, and certain epithelial or tumor cells. Structurally, ICOSLG contains extracellular immunoglobulin-like domains that mediate interaction with its receptor, ICOS (Inducible T-cell Costimulator), expressed on activated T cells. This ligand-receptor pair plays a critical role in modulating adaptive immune responses by providing secondary costimulatory signals for T-cell activation, proliferation, and cytokine production.
Recombinant ICOSLG proteins are engineered versions of this ligand, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functional integrity. These proteins often include the extracellular domain of ICOSLG, enabling studies of its binding properties without membrane-associated limitations. Researchers utilize recombinant ICOSLG to investigate immune synapse formation, T-cell differentiation (particularly Th2 and follicular helper T cells), and regulatory T-cell function. Its role in autoimmune diseases, allergic inflammation, and tumor immune evasion has made it a therapeutic target, with recombinant forms serving as tools for drug discovery, antibody development, and mechanistic studies. In therapeutic contexts, blocking ICOSLG-ICOS interactions is being explored to mitigate pathological immune activation, while agonist approaches aim to enhance antitumor immunity. Quality-controlled recombinant ICOSLG is also employed in diagnostic assays and as a reference standard in biomedical research.
×
